Baccili Camila Costa, Martin Camila Cecilia, Decaris Nathália, Madureira Karina Medici, Chase Christopher, Gomes Viviani
Department of Internal Medicine, College of Veterinary Medicine and Animal Science, University of Sao Paulo, 87, Prof. Dr. Orlando Marques de Paiva Avenue, Cidade Universitária, Butantã, Sao Paulo 05508-270, Brazil.
Department of Anatomy, Pathology and Clinical Medicine, Federal University of Bahia, 500, Adhemar de Barros Avenue, Ondina, Salvador40170-110, Brazil.
Vet Sci. 2019 Aug 26;6(3):69. doi: 10.3390/vetsci6030069.
After vaccination, vaccine components must activate the immune response, but the ideal vaccine should not result in undesirable effects in cattle. The aim of this study was to evaluate the inflammatory and humoral responses and adverse reactions induced by three adjuvanted commercial vaccines against bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BHV-1). Holstein heifers ( = 35) were divided into four groups by adjuvant compounds: Vaccine A (Alum; =9), Vaccine B (Oil-in-water; =10), Vaccine C (Amphigen/Quil A cholesterol and dimethyl-dioctadecyl ammonium (DDA) bromide (QAD; =10), and Control (=6). Heifers were assessed at 0 h, 6, 24, 48, 72 and 168 h post-vaccination; serology was evaluated at first dose (D0), booster (D21) and D42. Heifers vaccinated with Vaccine B (= 0.0001) and C (= 0.0001) had a more intense local reaction, while there was a higher rectal temperature detected in heifers vaccinated with Vaccine C (= 0.020). There was greater systemic reaction observed for heifers vaccinated with Vaccines B and C at 48h (= 0.002) after a second dose. Clinical pathology parameters [white blood count (WBC) ( = 0.001), neutrophils ( = 0.0001) and haptoglobin concentrations ( = 0.0001)] were higher in animals vaccinated with Vaccine C. Neutralizing Abs against BVDV type 1 strains, NADL and Singer, were detected in animals vaccinated with Vaccines A or C at D42, while BVDV-2 antibodies were detected only in animals vaccinated with Vaccine C. A BHV-1 antibody was detected in all three vaccine groups (Vaccines A, B or C) at day 42 (21 days post booster vaccination). The findings of this research were based on three different commercial laboratory formulations and also according to the conditions which the study was conducted. In this context, vaccine containing mineral oil or Amphigen/QAD presented greater local reactivity and induced a significant systemic inflammatory response. Vaccinated heifers with Alum and Amphigen/QAD commercial vaccines enhanced humoral immune response against BVDV and BHV-1.
接种疫苗后,疫苗成分必须激活免疫反应,但理想的疫苗不应在牛身上产生不良影响。本研究的目的是评估三种针对牛病毒性腹泻病毒(BVDV)和牛疱疹病毒1型(BHV-1)的佐剂商业疫苗诱导的炎症和体液反应以及不良反应。将荷斯坦小母牛(n = 35)按佐剂化合物分为四组:疫苗A(明矾;n = 9)、疫苗B(水包油;n = 10)、疫苗C(两性离子佐剂/皂树素胆固醇和二甲基二十八烷基溴化铵(QAD);n = 10)和对照组(n = 6)。在接种后0小时、6小时、24小时、48小时、72小时和168小时对小母牛进行评估;在首剂(D0)、加强免疫(D21)和D42时评估血清学。接种疫苗B(P = 0.0001)和C(P = 0.0001)的小母牛有更强烈的局部反应,而接种疫苗C的小母牛检测到更高的直肠温度(P = 0.020)。在第二次接种后48小时,接种疫苗B和C的小母牛观察到更大的全身反应(P = 0.002)。接种疫苗C的动物临床病理学参数[白细胞计数(WBC)(P = 0.001)、中性粒细胞(P = 0.0001)和触珠蛋白浓度(P = 0.0001)]更高。在D42时,接种疫苗A或C的动物检测到针对1型BVDV毒株NADL和Singer的中和抗体,而仅在接种疫苗C的动物中检测到BVDV-2抗体。在第42天(加强免疫接种后21天),在所有三个疫苗组(疫苗A、B或C)中均检测到BHV-1抗体。本研究结果基于三种不同的商业实验室配方,并根据研究进行的条件得出。在此背景下,含矿物油或两性离子佐剂/QAD的疫苗表现出更大的局部反应性,并诱导显著的全身炎症反应。接种明矾和两性离子佐剂/QAD商业疫苗的小母牛增强了针对BVDV和BHV-1的体液免疫反应。